X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs STRIDES SHASUN LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA STRIDES SHASUN LTD GLENMARK PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 13.9 14.0 99.2% View Chart
P/BV x 3.9 1.9 205.5% View Chart
Dividend Yield % 0.3 0.6 59.4%  

Financials

 GLENMARK PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-16
GLENMARK PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,2621,413 89.3%   
Low Rs672848 79.2%   
Sales per share (Unadj.) Rs270.6353.3 76.6%  
Earnings per share (Unadj.) Rs24.923.4 106.4%  
Cash flow per share (Unadj.) Rs34.441.0 84.0%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.20.4 46.8%  
Book value per share (Unadj.) Rs151.3320.4 47.2%  
Shares outstanding (eoy) m282.1689.35 315.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.63.2 111.7%   
Avg P/E ratio x38.948.3 80.4%  
P/CF ratio (eoy) x28.127.6 101.9%  
Price / Book Value ratio x6.43.5 181.1%  
Dividend payout %8.021.4 37.6%   
Avg Mkt Cap Rs m272,778100,988 270.1%   
No. of employees `00010.04.7 213.8%   
Total wages/salary Rs m13,7824,988 276.3%   
Avg. sales/employee Rs Th7,614.96,730.0 113.1%   
Avg. wages/employee Rs Th1,374.81,063.6 129.3%   
Avg. net profit/employee Rs Th700.2445.5 157.2%   
INCOME DATA
Net Sales Rs m76,34031,564 241.9%  
Other income Rs m3561,212 29.4%   
Total revenues Rs m76,69632,776 234.0%   
Gross profit Rs m14,1725,213 271.9%  
Depreciation Rs m2,6911,573 171.1%   
Interest Rs m1,7891,803 99.2%   
Profit before tax Rs m10,0483,049 329.5%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m3,028689 439.8%   
Profit after tax Rs m7,0192,089 335.9%  
Gross profit margin %18.616.5 112.4%  
Effective tax rate %30.122.6 133.5%   
Net profit margin %9.26.6 138.9%  
BALANCE SHEET DATA
Current assets Rs m59,09635,949 164.4%   
Current liabilities Rs m40,01819,402 206.3%   
Net working cap to sales %25.052.4 47.7%  
Current ratio x1.51.9 79.7%  
Inventory Days Days7571 105.7%  
Debtors Days Days119127 94.0%  
Net fixed assets Rs m39,07534,478 113.3%   
Share capital Rs m282894 31.6%   
"Free" reserves Rs m30,28122,601 134.0%   
Net worth Rs m42,70328,632 149.1%   
Long term debt Rs m24,87327,455 90.6%   
Total assets Rs m111,02676,591 145.0%  
Interest coverage x6.62.7 245.9%   
Debt to equity ratio x0.61.0 60.7%  
Sales to assets ratio x0.70.4 166.8%   
Return on assets %7.95.1 156.1%  
Return on equity %16.47.3 225.2%  
Return on capital %17.58.2 214.4%  
Exports to sales %43.348.1 89.9%   
Imports to sales %7.414.5 51.4%   
Exports (fob) Rs m33,04415,192 217.5%   
Imports (cif) Rs m5,6724,565 124.3%   
Fx inflow Rs m36,94516,612 222.4%   
Fx outflow Rs m61,0665,292 1,153.9%   
Net fx Rs m-24,12211,320 -213.1%   
CASH FLOW
From Operations Rs m3,449717 481.2%  
From Investments Rs m-8,802-22,284 39.5%  
From Financial Activity Rs m6,98629,488 23.7%  
Net Cashflow Rs m9348,073 11.6%  

Share Holding

Indian Promoters % 48.3 27.7 174.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 37.8 18.3%  
FIIs % 34.4 8.6 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   56,727 56,241 100.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS